Through purpose-driven science, empowering medicines, and transformative advocacy we seek to improve the lives of millions.

Uterine Fibroids

An estimated 5 million people in the U.S. suffer from symptoms of uterine fibroids.

Prostate Cancer

Approximately 3 million people alive today in the U.S. have been diagnosed with prostate cancer.

Thomasine’s journey through uterine fibroids started with pain but led to empowerment.

Myovant is developing innovative medicines that hold promise to improve people’s lives.

We’re partnering with cross-sector coalitions to fight stigma, raise awareness, and empower people with information.

Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022

Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021

Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference

View more news

Myovant Sciences Q3 2021 Earnings Conference Call

40th Annual J.P. Morgan Healthcare Conference

Evercore ISI 4th Annual HealthCONx Conference

Myovant Sciences Q2 2021 Earnings Conference Call

View more events

You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.